A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia

Stopped Development of JCAR015 has been discontinued. No subjects were enrolled/treated under protocol JCAR015-ALL-001

Conditions

• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions

• DRUG: JCAR015

Sponsor

Celgene

Collaborators

• [object Object]